论文部分内容阅读
目的观察糖耐量减低(IGT)患者应用罗格列酮治疗前后血浆内皮素(ET)、一氧化氮(NO)、C反应蛋白(C-RP)水平变化。方法经OGTT筛查出IGT患者72例,对其进行15周的随机、双盲、安慰剂对照、罗格列酮干预治疗试验。观察试验前后ET、NO、C-RP变化情况。结果罗格列酮组治疗15周后与治疗前相比,ET、C-RP下降,NO上升(P均<0.01),而安慰剂组三者差异无统计学意义。结论 IGT患者应用罗格列酮治疗可改善血浆ET、NO、C-RP水平。
Objective To observe the changes of plasma endothelin (ET), nitric oxide (NO) and C-reactive protein (C-RP) in patients with impaired glucose tolerance (IGT) before and after treatment with rosiglitazone. Methods Seventy two IGT patients were screened by OGTT, and were randomized, double-blind, placebo-controlled and rosiglitazone intervention trials for 15 weeks. Observed before and after the test ET, NO, C-RP changes. Results Compared with those before treatment, the levels of ET, C-RP and NO increased in rosiglitazone group after 15 weeks of treatment (all P <0.01), but there was no significant difference between the three groups in placebo group. Conclusion The application of rosiglitazone in IGT patients can improve the levels of plasma ET, NO and C-RP.